资讯

It’s no secret that obesity is becoming an epidemic in the United  States. It’s estimated that by 2030, 50 percent of Americans will be obese. But the reality  is, it’s not just Americans.   According ...
Two new studies that have been published recently show that people who have been taking weight loss drugs may have encountered an increased risk of serious eye conditions and vision loss.
WITH the price of Mounjaro set to rise and concerns about long-term affordability and access, many may be looking to turn to alternative treatments, like Wegovy. But how do the two weight loss ...
A WOMAN who’s lost almost five stone on Mounjaro has admitted she’s willing to get herself into debt to stay on it amid the upcoming price hike. The fat jab community was left panicked ...
Wegovy is the first GLP-1 treatment approved for MASH. Read more at straitstimes.com. Read more at straitstimes.com.
Novo Nordisk A/S’s weight-loss drug Wegovy has received FDA approval to treat a serious form of liver disease, giving the ...
Doctors and many patients say GLP-1 drugs can help solve the growing problem of obesity. But some bristle at the thought that ...
Hims & Hers saw 73% revenue growth, driven by subscriber gains and ARPU hikes. Read here for an in-depth investment analysis ...
The former This Morning presenter, 63, has long been open about her struggles with her weight, which have seen her fluctuate ...
Madrigal Pharmaceuticals, Inc.'s Rezdiffra saw Q2 net sales soar 55% to $212.8M amid strong growth. EU approval expected by ...
Eli Lilly raised the price of its GLP-1, Zepbound, from about $125 to $165 and plans an additional hike next month that would almost double its price. In a note to clients Friday, Bank of America ...
Studies have linked GLP-1 medications to various eye conditions, some of which may lead to vision loss. Despite these ...